LANXESS Aktiengesellschaft

XTRA:LXS Rapport sur les actions

Capitalisation boursière : €1.4b

LANXESS Résultats passés

Passé contrôle des critères 0/6

Les bénéfices de LANXESS ont diminué à un taux annuel moyen de -56%, tandis que le secteur Chemicals a vu ses bénéfices augmenter de en baisse à 4.4% par an. Les revenus ont augmenté de en baisse à un taux moyen de 2% par an.

Informations clés

-55.95%

Taux de croissance des bénéfices

-55.95%

Taux de croissance du BPA

Chemicals Croissance de l'industrie12.41%
Taux de croissance des recettes-2.05%
Rendement des fonds propres-18.87%
Marge nette-12.13%
Prochaine mise à jour des résultats07 Aug 2026

Mises à jour récentes des performances passées

Recent updates

Mise à jour du récit Jun 02

LXS: Fair Outlook Flags Limited Upside As Middle East Risk Deepens

LANXESS's fair value estimate is revised from €14.0 to €11.0 as analysts reset price targets following multiple downgrades, citing limited perceived upside after the share price rally, along with fresh concerns around pricing, demand resilience, and the balance sheet linked to the Middle East conflict. Analyst Commentary Recent research updates on LANXESS point to a clear shift toward caution, with several large houses cutting ratings and trimming price targets.
Article d’analyse May 09

Here's What Analysts Are Forecasting For LANXESS Aktiengesellschaft (ETR:LXS) After Its First-Quarter Results

LANXESS Aktiengesellschaft ( ETR:LXS ) shareholders are probably feeling a little disappointed, since its shares fell...
Mise à jour du récit May 01

LXS: Mixed Bank Ratings Will Drive Bullish Repricing On Higher Future P/E

Analysts have adjusted the price target on LANXESS from about €28.86 to about €26.29. This reflects updated views on faster revenue growth, much thinner profit margins, and a much higher assumed future P/E multiple after recent mixed rating changes from major banks.
Mise à jour du récit Apr 16

LXS: Future Earnings Multiples Will Balance Mixed Ratings And Margin Execution Risk

LANXESS' updated analyst price target edges up to about €17.91 from roughly €17.81, as analysts factor in slightly higher assumed revenue growth and a marginally richer future P/E, partly offset by a more cautious profit margin view following mixed recent rating changes. Analyst Commentary Recent research views on LANXESS are mixed, with both upgrades and a downgrade pointing to different expectations around execution, earnings power and valuation risk.
Mise à jour du récit Apr 02

LXS: Future Earnings Multiples Will Reflect Mixed Rating Shifts And Execution Risk

Analysts have trimmed the LANXESS price target from about €18.66 to around €17.81, reflecting mixed recent research that balances reduced fair value and profit margin assumptions with updated views on growth and valuation following both target cuts and rating changes across the Street. Analyst Commentary Recent research on LANXESS shows a split tape, with some firms turning more positive on the shares while others are taking a more cautious line on execution and fair value assumptions.
Mise à jour du récit Mar 19

LXS: Fair Outlook Balances Higher Risk Assumptions With Recent Upgrade

Analysts have trimmed their fair value estimate for LANXESS from €17.0 to €14.0, reflecting recent price target cuts such as Deutsche Bank's move to €17 and updated assumptions for growth, margins and risk, even as some research, including a recent Goldman Sachs upgrade, highlights potential longer term upside drivers. Analyst Commentary Recent research shows a split view on LANXESS, with some highlighting possible longer term drivers while others are reining in expectations.
Mise à jour du récit Mar 05

LXS: Upgrade And Reset Expectations Will Drive Bullish Repricing Potential

Analysts have adjusted their price targets on LANXESS, with the latest change lowering one view from €18.50 to €17. This reflects updated assumptions around discount rates, modest revenue growth and expected P/E levels.
Mise à jour du récit Feb 18

LXS: Upgrade And Margin Execution Are Expected To Drive Bullish Repricing

LANXESS's consensus analyst price target has moved modestly lower, with recent cuts to €17 and €15 cited by analysts who point to updated assumptions around discount rates, profit margins, and forward P/E expectations. Analyst Commentary Recent research on LANXESS highlights a mix of caution and optimism, with some bullish analysts focusing on potential upside if the company can execute against current expectations on margins and earnings quality.
Mise à jour du récit Feb 04

LXS: Sector Headwinds And Execution Discipline Will Drive Future Bullish Repricing

Analysts have trimmed their price expectations for LANXESS, reflected in a slightly lower fair value estimate of about €28.87 from €29.24. They cite a series of reduced Street price targets and more cautious sector views, even as underlying model assumptions such as revenue growth, profit margin and future P/E remain broadly consistent.
Mise à jour du récit Jan 21

LXS: Future Earnings Multiples Will Reward Execution Despite Sector Downgrades

Our fair value estimate for LANXESS has been reduced from about €20.30 to roughly €18.66, reflecting a cluster of lower price targets and more cautious views from analysts who now generally expect lower growth and apply a slightly higher required return. Analyst Commentary Recent Street research around LANXESS has tilted more cautious, with several firms trimming price targets and highlighting sector headwinds in European chemicals and ingredients.
Mise à jour du récit Jan 06

LXS: Earnings Resilience And Portfolio Actions Will Drive Bullish Repricing

Narrative Update The updated analyst price target framework for LANXESS points to a fair value adjustment from €31.85 to €29.24. This reflects recent target cuts from €21 to €15 at JPMorgan, a downgrade to Underweight with a €15 target at Barclays, and a reduction from €26 to €23 at Citi that collectively signal increased caution among analysts.
Article d’analyse Jan 02

A Look At The Fair Value Of LANXESS Aktiengesellschaft (ETR:LXS)

Key Insights The projected fair value for LANXESS is €14.85 based on 2 Stage Free Cash Flow to Equity LANXESS' €17.62...
Mise à jour du récit Dec 17

LXS: Demand Recovery And Margin Actions Will Drive Bullish Repricing

Analysts have trimmed their price target on LANXESS to EUR 15 from EUR 21, citing weaker expected revenue growth, lower profit margins, a higher discount rate, and a richer future P E multiple. Together, these factors reduce estimated fair value from about EUR 37.49 to EUR 31.85 per share.
Article d’analyse Dec 15

Does LANXESS (ETR:LXS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Mise à jour du récit Dec 03

LXS: Future Earnings Multiples Will Reward Improving Execution Amid Sector Caution

The analyst fair value estimate for LANXESS has been reduced slightly to EUR 20.30 from EUR 20.92, as analysts factor in lower sector sentiment, a modestly softer revenue growth outlook, and recent cuts to Street price targets across the European chemicals space. Analyst Commentary Street research on LANXESS has turned more cautious, with recent revisions reflecting concerns around sector headwinds, execution risk, and a less supportive valuation backdrop.
Mise à jour du récit Nov 19

LXS: Future Earnings Multiples Will Reflect Sector Caution And Resilient Performance

LANXESS’s analyst price target has been revised downward from €24.55 to €20.92 as analysts cite sector-wide caution and a reassessment of fair value within the European chemicals industry. Analyst Commentary The recent series of updates from street research highlights both supportive and cautious sentiment regarding LANXESS’s outlook, reflecting the evolving landscape in the European chemicals sector.
Mise à jour du récit Nov 05

LXS: Future Resilience Will Support Stability Amid Sector Pressures

Analysts have modestly reduced their price target for LANXESS by approximately EUR 0.30. This adjustment reflects more cautious growth and valuation assumptions in light of recent sector performance and peer comparisons.
Mise à jour du récit Oct 22

Analysts Lower LANXESS Price Target and Ratings Amid Mixed Outlook and Valuation Shifts

The analyst price target for LANXESS has been reduced by approximately EUR 0.67 to EUR 24.85. This change reflects revised expectations on revenue growth and profitability as analysts adjust their outlook in light of recent performance and updated industry assessments.
Mise à jour du récit Oct 08

Portfolio Optimization And Sustainable Initiatives Will Unlock Market Opportunities

The analyst consensus price target for LANXESS has been reduced from €26.79 to €25.52. Analysts cite increased caution due to reduced expected growth and valuation concerns following the company's recent outperformance among peers.
Mise à jour du récit Aug 29

Accelerated FORWARD! Program Set To Improve Future Performance

Analysts have lowered LANXESS's price target to €26.79, citing ongoing operational headwinds, margin pressure, and delayed recovery in key markets, while acknowledging that cost measures will take time to improve earnings. Analyst Commentary Bearish analysts cite persistent near-term operational headwinds and sluggish demand as reasons for lowering price targets.
Article d’analyse Jul 03

Is LANXESS Aktiengesellschaft (ETR:LXS) Trading At A 46% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, LANXESS fair value estimate is €47.92 LANXESS is estimated to...
User avatar
Nouveau récit Mar 22

Accelerated FORWARD! Program Set To Improve Future Performance

Successful cost savings and portfolio transformation initiatives are boosting profitability, improving margins, and enhancing future earnings potential through strategic divestitures.
Article d’analyse Mar 07

Why Investors Shouldn't Be Surprised By LANXESS Aktiengesellschaft's (ETR:LXS) 25% Share Price Surge

LANXESS Aktiengesellschaft ( ETR:LXS ) shareholders have had their patience rewarded with a 25% share price jump in the...
Article d’analyse Jan 31

LANXESS (ETR:LXS) Use Of Debt Could Be Considered Risky

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse Jan 07

Why We're Not Concerned About LANXESS Aktiengesellschaft's (ETR:LXS) Share Price

There wouldn't be many who think LANXESS Aktiengesellschaft's ( ETR:LXS ) price-to-sales (or "P/S") ratio of 0.3x is...
Article d’analyse Oct 30

Does LANXESS (ETR:LXS) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse Sep 07

Why We're Not Concerned About LANXESS Aktiengesellschaft's (ETR:LXS) Share Price

There wouldn't be many who think LANXESS Aktiengesellschaft's ( ETR:LXS ) price-to-sales (or "P/S") ratio of 0.3x is...
Article d’analyse Jul 23

Is LANXESS (ETR:LXS) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Article d’analyse May 27

Is It Too Late To Consider Buying LANXESS Aktiengesellschaft (ETR:LXS)?

While LANXESS Aktiengesellschaft ( ETR:LXS ) might not have the largest market cap around , it saw a double-digit share...
Article d’analyse May 08

Why Investors Shouldn't Be Surprised By LANXESS Aktiengesellschaft's (ETR:LXS) P/S

There wouldn't be many who think LANXESS Aktiengesellschaft's ( ETR:LXS ) price-to-sales (or "P/S") ratio of 0.4x is...
Article d’analyse Apr 20

Is There An Opportunity With LANXESS Aktiengesellschaft's (ETR:LXS) 42% Undervaluation?

Key Insights The projected fair value for LANXESS is €44.32 based on 2 Stage Free Cash Flow to Equity LANXESS is...
Article d’analyse Mar 22

Is LANXESS (ETR:LXS) Weighed On By Its Debt Load?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d’analyse Jan 27

What You Can Learn From LANXESS Aktiengesellschaft's (ETR:LXS) P/S

There wouldn't be many who think LANXESS Aktiengesellschaft's ( ETR:LXS ) price-to-sales (or "P/S") ratio of 0.3x is...
Article d’analyse Dec 05

Is LANXESS (ETR:LXS) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse Nov 01

A Look At The Fair Value Of LANXESS Aktiengesellschaft (ETR:LXS)

Key Insights The projected fair value for LANXESS is €20.51 based on Dividend Discount Model Current share price of...

Ventilation des recettes et des dépenses

Comment LANXESS gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

XTRA:LXS Recettes, dépenses et bénéfices (EUR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
31 Mar 265,450-6611,06593
31 Dec 255,673-5771,09196
30 Sep 255,888-2431,11897
30 Jun 256,148-1651,164102
31 Mar 256,360-1361,176105
31 Dec 246,366-1771,177104
30 Sep 246,319-6901,167105
30 Jun 246,322-8221,164102
31 Mar 246,422-9511,182100
31 Dec 236,714-8431,23899
30 Sep 237,251-2801,350102
30 Jun 237,835-651,438104
31 Mar 238,0561281,439105
31 Dec 228,0881841,398102
30 Sep 227,7941911,330100
30 Jun 227,1901471,22999
31 Mar 226,6601461,17196
31 Dec 216,1011161,10795
30 Sep 215,9251191,05099
30 Jun 215,8051051,018100
31 Mar 215,7728631,022105
31 Dec 206,1048921,056108
30 Sep 206,2378831,088110
30 Jun 206,4809381,110113
31 Mar 206,7682311,127113
31 Dec 196,8022551,115114
30 Sep 196,5592661,055105
30 Jun 196,6412431,066106
31 Mar 196,7462121,072106
31 Dec 186,8241901,084109
30 Sep 187,0661441,166110
30 Jun 186,9901381,167109
31 Mar 186,873631,165110
31 Dec 176,530231,111103
30 Sep 176,810731,103116
30 Jun 177,021831,087121
31 Mar 177,2521661,072124
31 Dec 167,6991921,116131
30 Sep 167,5902051,092128
30 Jun 167,6221841,093126
31 Mar 167,7841961,097128
31 Dec 157,9021651,078130
30 Sep 158,000821,060134
30 Jun 158,087761,048141

Des revenus de qualité: LXS n'est actuellement pas rentable.

Augmentation de la marge bénéficiaire: LXS n'est actuellement pas rentable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: LXS n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 56% par an.

Accélération de la croissance: Impossible de comparer la croissance des bénéfices de LXS au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable

Bénéfices par rapport au secteur d'activité: LXS n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Chemicals ( -13.5% ).


Rendement des fonds propres

ROE élevé: LXS a un retour sur capitaux propres négatif ( -18.87% ), car il n'est actuellement pas rentable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/08 07:01
Cours de l'action en fin de journée2026/06/05 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

LANXESS Aktiengesellschaft est couverte par 32 analystes. 15 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
James KnightBarclays
Anil ShenoyBarclays
Andres Castanos-MollorBerenberg